UBS Group
LEXX icon

UBS Group’s Lexaria Bioscience LEXX Stock Holding History

UBS Group’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.1K Sell
3,514
-20,573
-85% -$224K ﹤0.01% 7498
2025
Q4 		$223K Buy
24,087
+23,614
+4,992% +$335K ﹤0.01% 6521
2025
Q3 		$6.76K Buy
473
+68
+17% +$987 ﹤0.01% 8765
2025
Q2 		$5.28K Buy
+405
New +$6.98K ﹤0.01% 9188
2025
Q1 		– Sell
-8
Closed -$244 – 10505
2024
Q4 		$244 Buy
+8
New +$295 ﹤0.01% 9552
2024
Q1 		– Sell
-302
Closed -$5.67K – 9716
2023
Q4 		$5.67K Buy
+302
New +$5.83K ﹤0.01% 7770
2023
Q3 		– Sell
-7
Closed -$72 – 9741
2023
Q2 		$72 Sell
7
-302
-98% -$5.87K ﹤0.01% 8556
2023
Q1 		$12.6K Sell
309
-64
-17% -$2.73K ﹤0.01% 7433
2022
Q4 		$13.8K Sell
373
-54
-13% -$1.94K ﹤0.01% 8141
2022
Q3 		$16K Buy
427
+149
+54% +$6.37K ﹤0.01% 7691
2022
Q2 		$12K Buy
278
+100
+56% +$4.02K ﹤0.01% 7665
2022
Q1 		$9K Sell
178
-98
-36% -$5.54K ﹤0.01% 8554
2021
Q4 		$17K Buy
+276
New +$23.6K ﹤0.01% 8066

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

UBS Group's LEXX Position: Q1 2026 in Review

UBS Group reduced its Lexaria Bioscience (LEXX) stake by 85% in Q1 2026, selling an estimated $224K and leaving 3,514 shares worth $41.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7498.

UBS Group first reported a position in LEXX in Q4 2021 and has held it in 13 quarters since. The position peaked at $223K in Q4 2025. 25 funds tracked by Wall St. Rank hold LEXX as of Q1 2026.

  • UBS Group held 3,514 shares of Lexaria Bioscience worth $41.1K as of Q1 2026.
  • UBS Group sold 20,573 Lexaria Bioscience shares in Q1 2026, an estimated $224K.
  • Lexaria Bioscience made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7498 holding.
  • UBS Group first reported a position in Lexaria Bioscience in Q4 2021 and has held it in 13 quarters since.
  • UBS Group's Lexaria Bioscience position peaked at $223K in Q4 2025.
  • 25 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.